CD274 and non-small cell lung carcinoma: SP263, for example, is approved as a companion diagnostic test with durvalumab, which was recently approved in the European Union for use in locally advanced, unresectable non-small cell lung cancer in adults whose tumors express PD-L1 on ≥ 1% of tumor cells and whose disease has not progressed following platinum-based chemoradiation therapy [18].